Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: leigh aulper who wrote (1194)	10/15/2001 11:23:10 AM
From: LLLefty	Respond to of 1386

In selling its only revenue-producing drugs, I guess it means cearly PARS is going to move alone in running Phase III for Dex. Can't help but wonder whether there ever was an opportunity for it to partner with a major in moving ahead with the trials, which will be very expensive. Were there no negotiations at all the last few years? I guess the sale will give PARS the funding it needs to carry the financial burden itself--and, of course, reap the profits if it succeeds. Been along-time holder--and patient. What's the Hebrew word for it? Savlanoot?